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Abstract 
Low venous tone (LVT) occurs when the veins in the lower limbs can no longer 
sufficiently pump enough blood back to the heart. Symptoms may include dull aching 
and cramping, itching or tingling in the calves, swelling redness or any colour 
changes as well as thickening of the skin in the lower limbs (Comerota, 2009). The 
most common indication of LVT is dilated veins known as varicose veins(Glovicski et 
al., 2011). LVT is a disorder found more commonly in females. Conventional 
treatment for LVT includes vein ligation or stripping, elastic compression, valve 
reconstruction and sclerotherapy venous bypass(Van den Bos et al., 2009). Amongst 
other treatment, exercise has also proven to be effective as it increases circulation, 
by increasing blood returning to the heart (Behrens and Michlovitz, 2006). A variety 
of herbal supplements have been proven to be safe and effective in the treatment of 
LVT.A combination complementary medication of red leaf extract, butcher’s broom 
extract, horse chestnut extract and vitamin B6 has been formulated as an over-the-
counter product in South Africa, to treat LVT without any anticipated adverse effects 
(Venavine-Nativa, 2014). Red vine leaf extract has also been proven to be useful in 
the treatment of LVT. Previous studies on the red vine leaf extract have shown that it 
is an effective and safe source of treatment (Kaluset al., 2004). Studies done on 
horse chestnut extract have stated that the extract increases venous tone and 
decreases capillary permeability, and butcher’s broom extract has been proven to be 
effective in the treatment of LVT (Lim and Davies, 2009). There are currently no 
studies done on the combination of red vine leaf extract, butcher’s broom extract, 
horse chestnut extract and vitamin B6 on symptoms associated with LVT. 
 
The aim of this study is to determine the efficacy of a combination complementary 
medication of red vine leaf extract (360 mg), horse chestnut extract (60 mg), 
butcher’s broom extract (35 mg) and pyridoxine (vitamin B6) (3.2 mg) in the 
treatment of symptoms associated with LVT, using a venous clinical severity score 
questionnaire (VCSS). 
 
A double-blinded, placebo-controlled design will be conducted at the University of 
Johannesburg (UJ) Health Centre, over 12 weeks. This research sample will be 
shared with another researcher, Miss Xoliswa Mazibuko, who evaluated the quality 
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of life with the use of CIVIQ questionnaire when treating LVT with the combination of 
red leaf extract, butcher’s broom extract, horse chestnut extract and vitamin B6. This 
study investigated any changes in physical symptoms.  
 
Forty one female participants between the ages of 30 and 55 years were recruited 
via advertisement placed at the UJ Health Centre and on the University of 
Johannesburg Doornfontein campus. A total of thirty three participants had 
completed the study. At the initial consultation, all respondents will be screened to 
see if they qualify to participate in the study. After the screening procedure, 
participants were paired according to the severity of their symptoms. This was 
determined by the number of symptoms experienced by each participant as 
mentioned in the inclusion criteria; and their current age. Each participant was paired 
with another participant experiencing the same or similar severity of pain and current 
age, according to matched pairs and placed in group A or B. Participants in group A 
had received a placebo capsule consisting of starch amyral white, di calcium 
phosphate DC and magnesium stearate as in-actives (Venavine-Nativa, 2014) and 
participants in group B had received the capsule that contained the active 
ingredients red vine leaf extract (360 mg), horse chestnut extract (60 mg), butcher’s 
broom extract (35 mg) and pyridoxine (vitamin B6) (3.2 mg). Once they qualified to 
participate in the study, a consent form was signed and completed. Participants then 
completed a VCSS questionnaire, with the help of the researcher, to assess their 
symptoms. Participants were given medication for the next thirty days and were 
instructed to take one capsule every morning. Follow up consultations took place 
after every thirty days at which participants completed the VCSS questionnaire, with 
the help of the researcher, underwent a physical assessment and receive additional 
medication for the next thirty days. The final consultation took place after 12 weeks. 
 
The Friedman test showed that the experimental group had a statistically significant 
improvement for the pain outcome measure and total combined score of the VCSS 
questionnaire after the 12-week period. The Mann Whitney U test for inter-group 
analysis showed that there were statistically significant differences between the 
experimental group and the control group for the pain outcome measure after the 12-
week period, and for the venous oedema outcome measure at week 8 and week 12; 
and for the total combined sores of the VCSS questionnaire after the 12-week 
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period. 
 
Results from this study shows the herbal combination complementary medication, 
containing red vine leaf extract, horse chestnut extract, butcher’s broom extract and 
vitamin B6 is effective in treating physical symptoms of LVT, when using the total 
combined scores of VCSS questionnaire, thus accepting the hypothesis. Further 
research is however needed to validate and support these findings.  
Introduction 
Definition 
Low venous tone (LVT) occurs when the veins in the lower limbs cannot pump 
sufficient blood back to the heart, causing accumulation of blood and increasing 
venous pressure (Turpie, 2011). 
 
Epidemiology 
The prevalence of LVT is higher in females than in males; 40% of females 
experience symptoms of LVT whereas 17% of males may experience symptoms 
(Miessner et al., 2007). Approximately 50% of women between the ages of 40-50, 
and 75% of women between the ages of 60-70 experience some symptoms of LVT 
during their lifetime (Beede-Dimmer, 2005). 
 
Aetiology 
The usual and most likely cause of LVT is venous hypertension usually due to 
incompetent valves. Factors which contribute to this are prolonged standing, 
pregnancy, trauma, surgery and genetics (Durham and Hebert, 2012). Genetics my 
also plays a crucial part in the formation of varicose veins. Various studies have 
shown that varicose veins are much more prevalent in older people and may be 
asymptomatic for a long period of time (Krysa et al., 2012). Venous hypertension, 
due to incompetent valves takes place in either superficial veins, deep veins or 
perforating veins. Incompetent valves are due to weakness of the valves or damage 
to the valves caused by certain venous diseases such as thrombosis. Valvular 
incompetence takes place once the vein wall has been weakened or dilated 
preventing the normal functioning of valves in the vein (Glovicski et al., 2011). Once 
blood is not sufficiently transported back to the heart, venous blood starts to 
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accumulate and increases the pressure within the lower limbs. As pressure starts to 
increase, venous hypertension develops. Venous hypertension may cause valvular 
incompetence, reflux and even venous obstructions. Accumulation of venous blood 
may affect superficial veins as well as deeper veins (Eberhardt and Rafelto, 2005). 
Valvular incompetence or weakened valves with increased venous pressure cause 
superficial veins to become dilated or tortuous; these are known as varicose veins 
(Glovicski et al., 2011). 
Signs and symptoms 
LVT is a disorder affecting the lower limbs commonly presenting as dilated veins 
such as telangiectasia, reticular veins and varicose veins (Eberhardt and Rafelto, 
2005). Once the superficial and deep veins become affected, clinical manifestations 
such as oedema, cutaneous hyperpigmentation, fibrosis, dermatitis, pruritus and 
subcutaneous tissue damage start to occur. Venous oedema occurs when there is 
an accumulation of fluid between the interstitial spaces; pitting oedema occurs when 
there is protein in the interstitial fluid while turgor skin indicates that the symptom is 
more chronic (Behrens and Michlovitz, 2006). Patients experiencing LVT commonly 
complain about heavy, tired and painful legs which tend to worsen throughout the 
day; these are typical signs that the disease is progressing and becoming more 
chronic (Butcher, 2005). 
Treatment 
Initial treatment in most cases of LVT, is to reduce any primary symptoms in order to 
prevent any secondary complications; such as CVI that may arise (Goldman et al., 
2011). A non-invasive and most common treatment technique of LVT is elevation of 
the lower limbs (Cooper, 2013). Compression therapy is used to decrease any 
oedema in the lower extremities. It causes a compression in the greater part of the 
lower part of the limb and gradually reduces the oedema, by pushing fluid upwards, 
towards the knee and towards the heart (Moffat et al., 2009). Pharmacological 
treatment has also been effective in the treatment of LVT. Certain drugs have proven 
to have venoactive properties causing an improvement in venous tone and capillary 
permeability (Eberhardt and Rafelto, 2005). Ablative therapy is the use of thermal 
energy to create radiofrequency directly over the veins. This type of therapy is 
usually used when bigger veins such as the saphenous vein becomes distended due 
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to the accumulation of blood (Merchant and Pichot, 2005). Exercise is another 
effective treatment, as calf and foot muscles contact causing an increase in the 
upward flow of blood in the peripheral circulatory system. Exercise tends to 
rehabilitate muscles responsible for contraction, thereby reducing symptoms of LVT 
(Eberhardt and Rafelto, 2005). 
Venavine Intensive® is a combination of red vine leaf extract, butcher’s broom 
extract, horse chestnut extract and vitamin B6 that have been researched separately 
for the treatment of LVT resulting in mild to moderate CVI. It is available over the 
shelf for self-medication purposes and it has no recorded side effects, provided that 
the recommended dosage and frequency is used. 
Materials and method 
Research design 
This 12-week double-blinded, placebo-controlled study was conducted to explore the 
efficacy of a herbal combination complementary medication, containing red vine leaf 
extract, horse chestnut extract, butcher’s broom extract and vitamin B6 in the 
improvement of physical symptoms associated with LVT, using the VCSS 
questionnaire as an evaluation tool. 
Participants 
Forty one female participants between the ages of 30 and 55 years, were recruited 
via advertisements placed at the UJ Health Centre and on the University of 
Johannesburg Doornfontein campus. 
Selection of participants 
The initial consultation (week 0), consisted of signing of the Participant Information 
and Consent form, followed by a screening test which confirmed if participants 
qualified to participate in the study. 
Inclusion criteria 
Participants were included in the study if they were; 
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 Female 
 Between the ages of 30 and 55 years 
 Experienced at least three symptoms from CEAP C1-C4 of LVT which 
includes varicose veins, tired or heavy legs, pain in the legs, tingling calves, 
venous oedema, induration of the legs, brown discolouration in the legs, skin 
changes such as erythema in the legs 
 Symptoms were aggravated by walking/standing and symptoms were 
ameliorated by rest and limb elevation. 
 
Exclusion criteria 
Respondents were excluded from this study if they; 
 Were pregnant or lactating 
 Were on chronic medication for cardiovascular disorder 
 Had any chronic diseases that was not sufficiently managed 
 Experienced CEAPC5-C6 of LVT symptoms including venous ulceration 
 Had a previous history of deep vein thrombosis 
 Were on Warfarin or blood thinning medication 
 Had any liver or kidney pathologies 
 Were hypersensitive to any/all herbal extracts  
 Were on any treatment (herbal or conventional) for LVT 
 Used compression stockings or Kinesio Taping therapy. 
 
Materials 
A modified University of Johannesburg case taking form was used to record results 
from the physical examination. The venous clinical severity score (VCSS) has been 
previously validated (Vasquez and Muschauer, 2010) but was not created to replace 
CEAP but rather to compliment it as an assessment for LVT and CVI. Participants 
than completed the VCSS questionnaire, with the assistance of the researcher. 
 
Method 
Each participant was paired with another participant experiencing the same or similar 
severity of pain and current age, according to matched pairs. One participant from 
each pair was then placed into group A and one participant was placed into group B, 
Commented [RR1]: Check spelling with reference list  
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thereby placing the participant in either the experimental group or the control group. 
Medication was labelled as A or B. The researcher, supervisor and all participants 
were blinded as to which group was the experimental and control group. At the initial 
consultation (week 0), after signing the consent form and the screening took place , 
a physical examination was conducted. The physical examination included vital signs 
as well as a physical examination. Participants than completed the VCSS 
questionnaire, with the assistance of the researcher. Follow up consultations took 
place at week 4, week 8 and week 12. Participants were given medication for the 
following 30 days at follow-up consultations. Participants in the experimental group 
and the control group were given 30 capsules at each consultation (week 0, week 4 
and week 8) (ninety capsules in total) and instructed to take one capsule each 
morning after breakfast for a 12 week period. 
Data analysis 
Data was collected from the questionnaire and analysed statistically with the 
assistance of a statistician at STATKON UJ. 
Results 
Definitions of statistical tests used 
 The Friedman test- is a non-parametric test used to analyse results which 
have been repeated over a period of time. This test aims at analysing 
repeated measures of variance in the experimental group and the control 
group. 
 The Mann-Whitney U test- is used to test independent variables. The 
Mann-Whitney U test is used when variables are not normally distributed. 
It analyses changes across groups. 
 The Wilcoxon signed-rank test- is a non-parametric test used when 
comparing two related samples, when analysing any changes or 
differentiating between two mean ranks from related samples or matched 
pairs (Pallant, 2007). 
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Results of age distribution 
The Shapiro-Wilk test was used to determine whether age was normally distributed 
(p>0.05). 
  
Table 4.1 The Shapiro-Wilk test for age distribution 
Group Sig Mean 
Age Control 0.174 43,06 years 
Experimental 0.026 43,13 years 
 
Results from the Shapiro-Wilk test shows that age was normally distributed in the 
control group (p= 0.174) but was not normally distributed in the experimental group 
(p= 0.026)  
Results of pain outcome measure  
The mean value for the control group at initial consultations (week 0) was 1.61. After 
4 weeks, the mean value for the control group had a slight decrease to 1.22. Mean 
values showed an increase in pain from week 8 (mean= 1.39) to week 12 (mean= 
1.56) for the control group. According to the Friedman test results, the control group 
had an insignificant decrease of p= 0.317. 
On initial consultation (week 0), the pain outcome measure in the experimental group 
was 1.80. After the 12-week period the pain outcome measure decreased to 0.80. 
Results of varicose vein outcome measure 
After the 12-week period, the mean rank increased to 2.53. In the control group, 
symptoms increased at week 4 (mean= 2.56) as well week 12 (mean= 2.33), when 
compared to week 8 (mean= 2.44).   
At the Initial consultation (week 0), the mean rank for the experimental group showed 
a value of 2.33 and at week 4 (mean rank=2.87) there was an increase in the 
appearance of varicose veins. Symptoms associated with varicose veins had 
decreased at week 8 (mean rank=2.47) and returned to 2.33, matching results at 
week 0 (mean= 2.33) after the 12-week period. 
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Results of venous oedema outcome measure 
After the 12-week period, the control group had an increase in venous oedema 
outcome measure. Venous oedema increased after week 8 (mean rank= 2.67) and 
week 12 (mean rank= 2.69) for the control group.  
In the experimental group, on initial consultation (week 0), the mean rank for venous 
oedema outcome measure was 2.73; after the 12-week period it decreased to 2.17. 
Although there was a decrease in the mean rank of the experimental group, there 
was no statistically significant difference in either the experimental (p= 0.164) and 
control group (p= 0.246). 
Results of skin pigmentation 
Results obtained from Friedman test for both the control group and the experimental 
group for skin pigmentation outcome measure had decreased over the 12-week 
period. The control group had a mean rank of 2.64 at week 0, which had decreased 
to 2.44 after the 12-week period. The control group had a skin pigmentation outcome 
measure increase at week 8 (mean rank= 2.58). The experiment group had a mean 
rank of 2.57 at the initial consultation (week 0); this remained the same at week 4 
and decreased at week 8 (mean rank= 2.43). After a 12-week period the mean rank 
was 2.43.   
Results of inflammation outcome measure 
Symptoms of inflammation ranked higher in the control group than in the 
experimental group at week 0. Mean ranks of inflammation outcome measures, at 
initial consultation (week 0) was 2.78 for the control group. There was a decrease in 
the mean rank of the control group at week 4 (mean rank= 2.56) and week 8 (mean 
rank= 2.33). There was no further decrease after the 12-week period for the control 
group (mean rank= 2.33).  
At the initial consultation (week 0) the experimental group had mean rank of 2.57, 
which had remained the same at week 4. At week 8 the inflammation outcome 
measure had decreased (mean rank= 2.43) and remained the same after the 12-
week period (mean rank= 2.43) in the experimental group. 
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Results of shin circumference outcome measure 
Measurements were taken after participants were seated for 30 minutes.  
In the control group, the right leg had a mean of 29.81 cm. After the 12-week period, 
the mean had increased to 30.22 cm. The experimental group had a higher 
circumference. At week 0, the mean was 29.86 cm. The shin circumference 
decreased at week 4 (mean= 29.62 cm) and at week 8 (mean= 29.37 cm). After the 
12-week period the mean was 29.23 cm (right leg). 
At the initial consult (week 0), in the control group, the mean of the shin 
circumference of the left leg was 29.99 cm. After the 12-week period, the mean for 
the shin circumference outcome measure of the left leg had increased (mean= 30.48 
cm). In the experimental group at the initial consultation (week 0), the mean for the 
shin circumference was 29.71 cm; at week 4 (mean= 29.71 cm) had remained the 
same; and decreased after week 8 (mean= 29.33 cm). After the 12-week period the 
mean for the shin circumference of was 29.29 cm. 
Results of total combined scores of VCSS questionnaire 
Results showed that at week 0, the control group had a mean rank value of 2.72. At 
week 4, the mean rank decreased (mean rank= 2.00). The total combined score in 
the control group had increased at both week 8 (mean rank= 2.50) and after the 12-
week period of the study (mean rank= 2.78). 
At week 0, the experiment group showed a mean rank of 3.37. This decreased 
consecutively at week 4 (mean rank= 2.80), at week 8 (mean rank= 2.17) and after 
the 12-week period (mean rank= 1.67) in the experiment group. 
Discussion 
Age outcome measure 
The Shapiro-Wilk test was used to analyse whether the variable age, in either group, 
was normally distributed (p>0.05). Results showed the variable age in the control 
group was normally distributed (p= 0.174), but was not normally distributed in the 
experimental group (p= 0.026).  
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Pain outcome measure 
Results after a 12-week period showed that the combination complementary 
medication significantly decreased the pain outcome measure of the experimental 
group when compared to the control group. The mean value for pain experienced 
was 1.80 at week 0 and after the 12-week period, the mean value had decreased to 
0.80. The Friedman test showed a statistically significant change, p=0.001 for the 
experiment group after the 12-week period. 
Results according to the Mann-Whitney U test shows a statistically significant 
difference (p=0.016) after the 12-week period. 
After the 12-week period, the Wilcoxon signed rank test showed significant statistical 
changes in the pain outcome measure, after the 12-week period (p= 0.016). 
Varicose vein outcome measure 
After the 12-week period, the mean rank was 2.33, showing no change in symptoms 
of varicose veins, according to the Friedman test (p= 0.947). The mean rank for the 
experimental group after week 4 and week 8 showed that there was a slight 
aggravation in symptoms associated with varicose veins, but the aggravation was 
short lived and the appearance of the varicose veins returned to their initial state 
(week 0) in the experimental group. Results from Table 4.7 showed that after the 12-
week, the control group had a p-value of p= 0.947 and the experimental group had a 
p-value of p= 0.079, showing no statistical significant changes over time. 
When comparing results in the control group, the mean rank at week 0 was 2.47, 
and after the 12-week period, the mean rank was 2.53, showing an aggravation of 
varicose veins. 
Results show that the combination complementary medication was unsuccessful in 
removing varicose veins but may have prevented aggravations associated with 
existing varicose veins, further long term studies are required to confirm this. 
There was also no statistically significant difference for the Mann-Whitney U (inter-
group) test (p= 0.196) for varicose vein outcome measure after the 12-week period. 
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Venous oedema outcome measures 
Results according to the Friedman test shows that the control group had a 
statistically insignificant difference of p=0.246 and the experimental group had a 
statistically insignificant difference of p=0.164 after the 12-week period. However, 
results obtained from the Mann-Whitney U test, show there was a statistically 
significant difference at week 0, showing a higher incidence of venous oedema in the 
experimental (mean rank at week 0 was 2.73) when being compared to the control 
group (mean rank at week 0 was 2.53). Later results from the Mann-Whitney U test 
show a statistically significant decrease at week 8 (p= 0.030) and after the 12-week 
period (p= 0.012).   
After the 12-week period, the Wilcoxon signed rank test showed a statistically 
significant change in venous oedema, after week 0 (p= 0.043), after week 8 (p= 
0.030) and after the 12 week period (p= 0.012). 
Skin pigmentation outcome measure 
In the experimental group, there was no increase of skin pigmentation. At week 0, 
the experimental group had a mean rank of 2.57 and had remained the same at 
week 4. Skin pigmentation outcome measures decreased at week 8 (mean rank= 
2.43) and remained the same after the 12-week period in the experimental group. 
Although the decrease was not constant, there was no aggravation or increase of 
skin pigmentation. 
After the 12-week period, the control group had a statistically insignificant difference 
of p= 0.439 and the experimental group had an insignificant significant difference of 
p= 0.392 according to Friedman test. Results from the Mann-Whitney U test show a 
statistically insignificant difference of p= 0.190 between the groups after 12-weeks. 
Although there is no statistically significant difference according to Friedman test and 
the Mann-Whitney U test, subjective results reported by participants show that the 
herbal complementary combination slightly decreased the skin pigmentation and 
prevented any further pigmentary changes in the experimental group (mean rank at 
week 0= 2.57; week 4= 2.57; week 8= 2.43 and week 12= 2.43). 
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Inflammation outcome measure 
Results from the Friedman test showed that the presence of inflammation in the 
control group was 2.78. Inflammation outcome measures in the control group 
decreased at week 4 (mean rank= 2.56) and week 8 (mean rank= 2.33). After the 
12-week period, the mean rank in the control group remained the same as week 8 
(mean rank= 2.33).  
After the 12-weeks period, according to the Mann-Whitney test, there was no 
statistical significant difference, p=0.361. 
Results after the 12-week period had showed the herbal combination complementary 
medication had no effect on inflammation as both the control and experimental 
groups decreased from week 4 to week 8; however this did not change from week 8 
to week 12. 
Shin circumference outcome measure   
According to Friedman test results for the shin circumference outcome measure, in 
the control group, both the right and left leg had increased in circumference. This 
increase was consecutive and increased at week 4, 8 and 12. In the experimental 
group shin circumference for the left leg had remained the same from week 0 
(mean= 29.71cm) to week 4 (mean= 29.71cm) for the experimental group. The shin 
circumference outcome measure for the experimental group had decreased at week 
8 (mean= 29.33cm) and 12 (mean= 29.29cm) in the left leg. The shin circumference 
outcome measure in the experimental group for the right leg had decreased at week 
4 (mean= 29.62cm), week 8 (mean= 29.37cm) and after the 12-week period (mean= 
29.23cm)   
Even though the shin circumference in both legs of participants in the experiment 
group had decreased successively results from the Mann-Whitney U test showed no 
significant difference, p=0.198 for the right leg and p=0.138 for the left legafter the 
12-week period. 
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Overall results of VCSS questionnaire 
 
 
In the experimental group, results from the Friedman test showed that there was a 
statistically significant difference (p=0.000) in the total combined score of the VCSS 
questionnaire after the 12-week period. The control group had a statistically 
insignificant difference (p= 0.129) after the 12-week study. 
After the 12-week period the Wilcoxon signed rank test showed a statistically 
significant change in total combined scores of the VCSS questionnaire had after 
week 8 (p= 0.024) and after the 12-week period (p= 0.001). 
Results from the Mann-Whitney U test shows a statistically difference at week 8 (p= 
0.024) and after the 12-week period (p= 0.001)showing overall significant 
improvement in the experimental group when compared to the control group. 
Results from this study shows the herbal combination complementary medication, 
containing red vine leaf extract, horse chestnut extract, butcher’s broom extract and 
vitamin B6 is effective in treating physical symptoms of LVT, when using the total 
combined scores of VCSS questionnaire, thus accepting the hypothesis. Further 
research is however needed to validate and support these findings.  
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